調査レポートカテゴリー： visiongain

Global Cancer Immunotherapy Market Forecast 2019-2029 : Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centres, Clinics

ウエハーレベルパッケージングの世界市場2019-2029：モノクローナル抗体、サイトカイン・免疫調節剤、免疫チェックポイント阻害剤、細胞療法、腫瘍崩壊性ウイルス免疫療法、肺がん、乳がん、大腸がん、黒色腫、前立腺がん、頭頸部がん、病院、がん研究センター、診療所

◆タイトル：Global Cancer Immunotherapy Market Forecast 2019-2029 : Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centres, Clinics
◆商品コード：VGN902094
◆調査・発行会社：visiongain
◆発行日：2019年1月
◆ページ数：194
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Sigle UserGBP3,499 ⇒換算￥0見積依頼/購入/質問フォーム
Departmental/Five UserGBP3,899 ⇒換算￥0見積依頼/購入/質問フォーム
Site LicenseGBP4,999 ⇒換算￥0見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

 【レポートの概要】

本調査レポートでは、"ウエハーレベルパッケージングの世界市場2019-2029：モノクローナル抗体、サイトカイン・免疫調節剤、免疫チェックポイント阻害剤、細胞療法、腫瘍崩壊性ウイルス免疫療法、肺がん、乳がん、大腸がん、黒色腫、前立腺がん、頭頸部がん、病院、がん研究センター、診療所"について調査・分析し、レポートサマリー、世界市場規模・市場予測、地域別市場分析、用途別分析、主要企業分析、結論などの情報をお届けいたします。

The world cancer immunotherapy market is expected to grow at a CAGR of 11.4% in the second half of the forecast period. The market reached $63bn in 2018, dominated by the monoclonal antibody segment which held 66% share of the market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 194-page report you will receive 110 tables and 93 figures– all unavailable elsewhere.

The 194-page report provides clear detailed insight into the global cancer-treating drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global cancer immunotherapy market forecasts from 2019-2029

• This report also breaks down the revenue forecast for the global cancer immunotherapy market by Technology:
• Monoclonal Antibodies
• Cytokines & immunomodulators
• Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

• This report also breaks down the revenue forecast for the global cancer immunotherapy market by Application:
• Lung Cancer
• Breast Cancer
• Colorectal cancer
• Melanoma Cancer
• Prostate Cancer
• Head & Neck Cancer,
• Others (Renal Cell Carcinoma, Cervical, Gastric, Lymphoma)

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

• This report also breaks down the revenue forecast for the world cancer immunotherapy market by End-User:
• Hospitals
• Cancer Research Centers
• Clinics

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

• This report provides individual revenue forecasts to 2029 for these regional and national markets:
• North America: US, Canada, Mexico
• South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America
• Europe: The UK, Germany, France, Spain, Italy, Rest of Europe
• Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific
• Rest of World: Middle East, Africa, Other Countries

Each regional market is further broken down by technology, application and end-user.

• This report discusses trends in the industry and assesses drivers and restraints, as well as opportunities and threats. It also includes porters’ five force analysis; threat of new entrants, power of suppliers, power of buyers, rivalry among competitors and threat of substituents.

• Our study discusses the selected leading companies that are the major players in the cancer immunotherapy market:
• Adaxic Inc
• AstraZeneca
• Bayer
• Bristol-Myers Squibb (BMS)
• Eli Lilly and Co.
• Medtronic Plc
• Merck & Co., Inc. (Merck)
• Novartis
• Pfizer
• Roche

The report provides overviews of the companies, financial information, product portfolio, pipeline products and recent developments.

Visiongain’s study is intended for anyone requiring commercial analyses for the global cancer Immunotherapy market. You find data, trends and predictions.

【レポートの目次】

1. Report Overview
1.1 Global Cancer Immunotherapy Market Overview
1.2 Market Definition
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Market Evaluation & Forecasting Methodology
1.4 Global Cancer Immunotherapy Market Segmentation
1.5 Overview of Findings
1.6 Why You Should Read This Report
1.7 How this report delivers?
1.8 Key Questions Answered by This Analytical Report
1.9 Frequently Asked Questions (FAQ)
1.10 Who is This Report For?
1.11 Associated Visiongain Reports
1.12 About Visiongain

2. Introduction to Cancer Immunotherapy Market

3. Global Cancer Immunotherapy Market Forecast 2019 – 2029

4. Global Cancer Immunotherapy Market by Technology: Market Forecast 2019 – 2029
4.1 Overview
4.2 Monoclonal antibodies
4.3 Cytokines & Immunomodulators
4.4 Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)

5. Global Cancer Immunotherapy Market by Application: Market Forecast 2019 – 2029
5.1 Overview
5.2 Lung Cancer
5.3 Breast Cancer
5.4 Colorectal Cancer
5.5 Melanoma
5.6 Prostate Cancer
5.7 Head & Neck Cancer
5.8 Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)

6. Global Cancer Immunotherapy Market by End-User: Market Forecast 2019 – 2029
6.1 Hospitals
6.2 Cancer Research Centres
6.3 Clinics

7. Regional Cancer Immunotherapy Market Forecasts 2019-2029
7.1 Regional Cancer Immunotherapy Market Forecast 2018-2029
7.2 North American Cancer Immunotherapy Market Forecast 2018-2029
7.2.1 USA Cancer Immunotherapy Market Forecast 2018-2029
7.2.2 Canada Cancer Immunotherapy Market Forecast 2018-2029
7.2.3 Mexico Cancer Immunotherapy Market Forecast 2018-2029
7.3 South American Cancer Immunotherapy Market Forecast 2018-2029
7.3.1 Brazil Cancer Immunotherapy Market Forecast 2018-2029
7.3. 2 Argentina Cancer Immunotherapy Market Forecast 2018-2029
7.3.3 Paraguay Cancer Immunotherapy Market Forecast 2018-2029
7.3.4 Bolivia Cancer Immunotherapy Market Forecast 2018-2029
7.3.5 Rest of South America Cancer Immunotherapy Market Forecast 2018-2029
7.4 European Cancer Immunotherapy Market Forecast 2018-2029
7.4.1 France Cancer Immunotherapy Market Forecast 2018-2029
7.4.2 Germany Cancer Immunotherapy Market Forecast 2018-2029
7.4.3 UK Cancer Immunotherapy Market Forecast 2018-2029
7.4.4 Spain Cancer Immunotherapy Market Forecast 2018-2029
7.4.5 Italy Cancer Immunotherapy Market Forecast 2018-2029
7.4.6 Rest of Europe Cancer Immunotherapy Market Forecast 2018-2029
7.5 Asia-Pacific Cancer Immunotherapy Market Forecast 2018-2029
7.5.1 China Cancer Immunotherapy Market Forecast 2018-2029
7.5.2 Japan Cancer Immunotherapy Market Forecast 2018-2029
7.5.3 India Cancer Immunotherapy Market Forecast 2018-2029
7.5.4 Australia Cancer Immunotherapy Market Forecast 2018-2029
7.5.5 Thailand Cancer Immunotherapy Market Forecast 2018-2029
7.5.6 Rest of Asia-Pacific Cancer Immunotherapy Market Forecast 2018-2029
7.6 Rest of World Cancer Immunotherapy Market Forecast 2018-2029
7.6.1 Middle East Cancer Immunotherapy Market Forecast 2018-2029
7.6.2 Africa Cancer Immunotherapy Market Forecast 2018-2029
7.6.3 Other Countries Cancer Immunotherapy Market Forecast 2018-2029

8. Cancer Immunotherapy Market: Qualitative Analysis
8.1 Porter’s Five Forces Analysis of the Cancer Immunotherapy Market
8.2 Bargaining Power of Buyers (Low)
8.3 Bargaining Power of Suppliers (High)
8.4 Threat of New Entrants (Low)
8.5 Threat of Substitute Products (High)
8.6 Intensity of Competitive Rivalry (High)
8.7 Drivers & Restrains
8.8 Increasing Prevalence of Cancer
8.9 Increasing Research in Cancer Immunotherapy
8.10 High Cost of Cancer Immunotherapy
8.11 Increasing Funding for the Cancer Research by Governmental Organisations
8.12 Increasing Investment from Government, Public and Private Sector
8.13 Increased Focus Towards Advanced Treatment Protocols
8.14 Significant Unmet Need in Cancer Diagnosis
8.15 Increased Awareness to Reduce Healthcare Costs
8.16 Opportunities in Emerging Economies

9. Leading Companies in Cancer Immunotherapy Market
9.1 F. Hoffmann-La Roche AG
9.1.1 F. Hoffmann-La Roche AG: Company Overview
9.1.2 F. Hoffmann-La Roche AG: Business Performance
9.1.3 F. Hoffmann-La Roche AG: Product Portfolio
9.1.4 F. Hoffmann-La Roche AG: Recent Developments
9.2 Merck & Co., Inc.
9.2.1 Merck & Co., Inc.: Company Overview
9.2.2 Merck & Co., Inc.: Business Performance
9.2.3 Merck & Co., Inc.: Product Portfolio
9.2.4 Merck & Co., Inc.: Recent Development
9.3 Medtronic plc.
9.3.1 Medtronic plc.: Company Overview
9.3.2 Medtronic plc.: Business Performance
9.3.3 Medtronic plc.: Product Portfolio
9.3.4 Medtronic plc.: Recent Developments
9.4 Bristol-Myers Squibb
9.4.1 Bristol-Myers Squibb: Company Overview
9.4.2 Bristol-Myers Squibb: Business Performance
9.4.3 Bristol-Myers Squibb: Product Portfolio
9.4.4 Bristol-Myers Squibb: Recent Developments
9.5 Novartis AG
9.5.1 Novartis AG: Company Overview
9.5.2 Novartis AG: Business Performance
9.5.3 Novartis AG: Product Portfolio
9.5.4 Novartis AG: Recent Developments
9.6 Pfizer Inc.
9.6.1 Pfizer Inc.: Company Overview
9.6.2 Pfizer Inc.: Business Performance
9.6.3 Pfizer Inc.: Product Portfolio
9.6.4 Pfizer Inc.: Recent Developments
9.7 Bayer AG
9.7.1 Bayer AG: Company Overview
9.7.2 Bayer AG: Business Performance
9.7.3 Bayer AG: Product Portfolio
9.7.4 Bayer AG: Recent Development
9.8 AstraZeneca Plc.
9.8.1 AstraZeneca Plc.: Company Overview
9.8.2 AstraZeneca Plc.: Business Performance
9.8.3 AstraZeneca Plc.: Product Portfolio
9.9 Eli Lilly and Company
9.9.1 Eli Lilly and Company: Company Overview
9.9.2 Eli Lilly and Company: Business Performance
9.9.3 Eli Lilly and Company: Product Portfolio
9.9.4 Eli Lilly and Company: Recent Development
9.10 Advaxis, Inc.
9.10.1 Advaxis, Inc.: Recent Development
9.10.2 Advaxis, Inc.: Business Performance
9.10.3 Advaxis, Inc.: Recent Development

10. Conclusions
10.1 Current Leading Segments
10.2 Leading Regional Markets
10.3 Emerging Markets
10.4 The Future of the Market?

Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Tables
Table 2.1. Worldwide Estimated Incidence and Prevalence of all Cancer Types, (2012)
Table 3.1. Global Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%) 2018-2029
Table 4.1. Global Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
Table 4.2. Types of Monoclonal Antibodies
Table 4.3. Therapeutic Monoclonal Antibodies Approved by FDA
Table 4.4. Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 4.5. Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%) 2018-2029
Table 4.6. Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 4.7. Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast by Geography:($m, AGR%, CAGR%), 2018-2029
Table 4.8. Global Others Technologies for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 4.9. Global Other Technologies for Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.1. Top Cancer Type in 2012
Table 5.2. Global Cancer Immunotherapy Market by Application: ($m, AGR%, CAGR%), 2018-2029
Table 5.3. Types of Monoclonal Antibodies
Table 5.4. Global Cancer Immunotherapy Market for Lung Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.5. Global Cancer Immunotherapy Market for Lung Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.6. Global Cancer Immunotherapy Market for Breast Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.7. Global Cancer Immunotherapy Market for Breast Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.8. Global Cancer Immunotherapy Market for Colorectal Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.9. Global Cancer Immunotherapy Market for Colorectal Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.10. Global Cancer Immunotherapy Market for Melanoma Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.11. Global Cancer Immunotherapy Market for Melanoma Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.12. Global Cancer Immunotherapy Market for Prostate Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.13. Global Cancer Immunotherapy Market for Prostate Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.14. Global Cancer Immunotherapy Market for Head & Neck Cancer: ($m, AGR%, CAGR%), 2018-2029
Table 5.15. Global Cancer Immunotherapy Market for Head & Neck Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 5.16. Global Cancer Immunotherapy Market for Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma): ($m, AGR%, CAGR%) 2018-2029
Table 5.17. Global Cancer Immunotherapy Market for Other Cancer Types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma) by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 6.1. Global Cancer Immunotherapy Market by End-User: ($m, AGR%, CAGR%), 2018-2029
Table 6.2. Global Cancer Immunotherapy Market Forecast for Hospital: ($m, AGR%, CAGR%), 2018-2029
Table 6.3. Global Cancer Immunotherapy Market Forecast for Hospital by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 6.4. Funding Received by NCI ($m)
Table 6.5. Current Grants by Cancer Type as of August 2018
Table 6.6. Global Cancer Immunotherapy Market for Cancer Research Centres: ($m, AGR%, CAGR%), 2018-2029
Table 6.7. Global Cancer Immunotherapy Market Forecast for Cancer Research Centres by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 6.8. Global Cancer Immunotherapy Market Forecast for Clinic: ($m, AGR%, CAGR%), 2018-2029
Table 6.9. Global Cancer Immunotherapy Market Forecast for Clinic by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 7.1. Global Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%), 2018-2029
Table 7.2. North America Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
Table 7.3. North America Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
Table 7.4. North America Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
Table 7.5. North America Cancer Immunotherapy Market Forecast by End User: ($m, AGR%, CAGR%), 2018-2029
Table 7.6. US Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.7. Canada Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.8. Mexico Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.9. South America Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
Table 7.10. South America Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
Table 7.11. South America Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
Table 7.12. South America Cancer Immunotherapy Market Forecast by End User: ($m, AGR%, CAGR%), 2018-2029
Table 7.13. Brazil Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.14. Argentina Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.15. Paraguay Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.16. Bolivia Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.17. Rest of South America Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.18. European Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
Table 7.19. European Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
Table 7.20 European Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
Table 7.21 European Cancer Immunotherapy Market Forecast by End-User: ($m, AGR%, CAGR%), 2018-2029
Table 7.22. France Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.23. Germany Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.24. UK Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.25. Spain Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.26. Italy Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.27. Rest of European Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.28. Asia-Pacific Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
Table 7.29. Asia-Pacific Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%,), 2018-2029
Table 7.30. Asia-Pacific Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
Table 7.31 Asia-Pacific Cancer Immunotherapy Market Forecast by End- User: ($m, AGR%, CAGR%), 2018-2029
Table 7.32. China Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.33. Japan Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.34. India Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.35. Australia Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.36. Thailand Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.37. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.38. Rest of World Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029
Table 7.39. Rest of World Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029
Table 7.40 Rest of World Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029
Table 7.41 Rest of World Cancer Immunotherapy Market Forecast by End-User: ($m, AGR%, CAGR%), 2018-2029
Table 7.42. Middle East Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.43. Africa Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 7.44. Other Countries Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029
Table 9.1. F. Hoffmann-La Roche AG: Company Overview
Table 9.2. F. Hoffmann-La Roche AG: Product Portfolio
Table 9.3. F. Hoffmann-La Roche AG: Recent Developments
Table 9.4. Merck & Co., Inc.: Company Overview
Table 9.5. Merck & Co., Inc.: Product Portfolio
Table 9.6. Merck & Co., Inc.: Recent Development
Table 9.7. Medtronic plc.: Company Overview
Table 9.8. Medtronic plc.: Product Portfolio
Table 9.9. Medtronic plc.: Recent Developments
Table 9.10. Bristol-Myers Squibb: Company Overview
Table 9.11. Bristol-Myers Squibb: Product Portfolio
Table 9.12. Bristol-Myers Squibb: Recent Developments
Table 9.13 Novartis AG: Company Overview
Table 9.14. Novartis AG: Product Portfolio
Table 9.15. Novartis AG: Recent Developments
Table 9.16. Pfizer Inc.: Company Overview
Table 9.17. Pfizer Inc.: Product Portfolio
Table 9.18. Pfizer Inc.: Recent Development
Table 9.19. Bayer AG: Company Overview
Table 9.20. Bayer AG: Product Portfolio
Table 9.21. Bayer AG: Recent Development
Table 9.22. AstraZeneca Plc.: Company Overview
Table 9.23. AstraZeneca Plc.: Product Portfolio
Table 9.24. Eli Lilly and Company: Company Overview
Table 9.25. Eli Lilly and Company: Product Portfolio
Table 9.26. Eli Lilly and Company: Recent Development
Table 9.27. Advaxis, Inc.: Company Overview
Table 9.28. Advaxis, Inc.: Recent Developments
Table 10.1 Worldwide Estimated Prevalence of Cancer, 2012

List of Figures
Figure 1.1. Cancer immunotherapy Market Segmentation
Figure 2.1 Top winning Strategies of Market Players in Cancer Immunotherapy, 2014-2018
Figure 3.1 Cancer Immunotherapy Market by Technology: ($m), 2018-2029
Figure 3.2 Cancer Immunotherapy Market by Application: ($m), 2018-2029
Figure 3.3 Cancer Immunotherapy Market by End-User: ($m), 2018-2029
Figure 4.1 Cancer Immunotherapy Market by Technology: Market Share (%), 2018
Figure 4.2 Cancer Immunotherapy Market by Technology: Forecast ($m) 2018-2029
Figure 4.3 Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast by Geography: ($m) 2018-2029
Figure 4.4 Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029
Figure 4.5 Global Other Technologies for Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029
Figure 5.1. Global Cancer Immunotherapy Market by Application: ($m), 2018-2029
Figure 5.2. Global Cancer Immunotherapy Market by Application: Market Share (%), 2018
Figure 5.3. Global Cancer Immunotherapy Market for Lung Cancer Forecast by Geography: ($m), 2018-2029
Figure 5.4. Global Cancer Immunotherapy Market for Breast Cancer Forecast by Geography: ($m), 2018-2029
Figure 5.5. Global Cancer Immunotherapy Market for Colorectal Cancer Forecast, by Geography: ($m), 2018-2029
Figure 5.6. Global Cancer Immunotherapy Market for Melanoma Cancer Forecast by Geography: ($m), 2018-2029
Figure 5.7. Global Cancer Immunotherapy Market for Prostate Cancer Forecast, by Geography: ($m), 2018-2029
Figure 5.8. Global Cancer Immunotherapy Market for Head & Neck Cancer Forecast by Geography: ($m), 2018-2029
Figure 5.9. Global Cancer Immunotherapy Market for Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma) Forecast by Geography: ($m), 2018-2029
Figure 6.0. Global Cancer Immunotherapy Market Forecast by End-User: ($m), 2018-2029
Figure 6.1 Global Cancer Immunotherapy Market by End-User: Market Share (%), 2018
Figure 6.2. Global Cancer Immunotherapy Market Forecast for Hospital by Geography: ($m), 2018-2029
Figure 6.3. Global Cancer Immunotherapy Market Forecast for Cancer Research Centres by Geography: ($m), 2018-2029
Figure 6.4 Global Cancer Immunotherapy Market Forecast for Clinic by Geography: ($m), 2018-2029
Figure 7.1. Global Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029
Figure 7.2. Global Cancer Immunotherapy Market Forecast by Geography: Market Share (%), 2018
Figure 7.3. North America Cancer Immunotherapy Market by Country: Market Share (%), 2018
Figure 7.4. US Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.5. Estimation of diagnosis of Canadian Cancer Immunotherapy
Figure 7.6. Cancer Immunotherapy Market Forecast ($m), 2018-2029
Figure 7.7 Mexico Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.8 South America Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029
Figure 7.9 South America Cancer Immunotherapy Market by Country: Market Share (%), 2018
Figure 7.10. Brazil Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.11. Argentina Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.12. Paraguay Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.13. Bolivia Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.14. Rest of South America Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.15. Europe Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029
Figure 7.16. Europe Cancer Immunotherapy Market by Country: Market Share (%), 2018
Figure 7.17. France Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.18. Germany Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.19. UK Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.20. Spain Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.21. Italy Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.22. Rest of Europe Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.23. Asia-Pacific Cancer Immunotherapy Market Forecast by Country ($m) 2018-2029
Figure 7.24. Asia-Pacific Cancer Immunotherapy Market: Market Share (%), 2018
Figure 7.25. China Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.26. Japan Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.27. India Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.28. Australia Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.29. Thailand Cancer Immunotherapy Market Forecast: ($m,) 2018-2029
Figure 7.30. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.31. RoW Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029
Figure 7.32. Rest of World Cancer Immunotherapy Market by Country: Market Share (%), 2018
Figure 7.33. Middle East Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.34. Africa Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 7.35. Other Countries Cancer Immunotherapy Market Forecast: ($m), 2018-2029
Figure 8.1 Porter’s Five Forces Analysis of the Cancer Immunotherapy Market
Figure 9.1. F. Hoffmann-La Roche AG: Historical Revenue: ($m), 2013-2017
Figure 9.2. F. Hoffmann-La Roche AG: Product Segments Share (%), 2017
Figure 9.3. F. Hoffmann-La Roche AG: Geographical Presence Share (%), 2017
Figure 9.4. Merck & Co., Inc.: Historical Revenue ($m), 2013–2017
Figure 9.5. Merck & Co., Inc.: Product Segments Share (%), 2017
Figure 9.6. Merck & Co., Inc.: Geographical Presence Share (%), 2017
Figure 9.7. Medtronic plc.: Historical Revenue ($m), 2014-2018
Figure 9.8. Medtronic plc.: Product Segments Share (%), 2018
Figure 9.9. Medtronic plc.: Geographical Presence Share (%), 2018
Figure 9.10. Bristol-Myers Squibb: Historical Revenue ($m), 2013-2017
Figure 9.11. Bristol-Myers Squibb: Product Segments Share (%), 2017
Figure 9.12. Bristol-Myers Squibb: Geographical Presence Share (%), 2017
Figure 9.13. Novartis AG: Historical Revenue ($m), 2013-2017
Figure 9.14. Novartis AG: Product Segments Share (%), 2017
Figure 9.15. Novartis AG: Geographical Presence Share (%), 2017
Figure 9.16. Pfizer Inc., Historical Revenue, ($m), 2013-2017
Figure 9.17. Pfizer Inc.: Product Segments Share (%), 2017
Figure 9.18. Pfizer Inc.: Geographical Presence Share (%), 2017
Figure 9.19. Bayer AG: Historical Revenue, ($m), 2013-2017
Figure 9.20. Bayer AG: Product Segments Share (%), 2017
Figure 9.21. Bayer AG: Geography Presence Share (%), 2018
Figure 9.22. AstraZeneca Plc.: Historical Revenue, ($m), 2013-2017
Figure 9.23. AstraZeneca Plc.: Product Segments Share (%), 2017
Figure 9.24. AstraZeneca Plc.: Geographical Presence Share (%), 2017
Figure 9.25. Eli Lilly and Company: Historical Revenue ($m), 2013-2018
Figure 9.26. Eli Lilly and Company: Product Segments Share (%), 2017
Figure 9.27. Eli Lilly and Company: Geographical Presence Share (%), 2017
Figure 9.28. Advaxis, Inc.: Historical Revenue ($m), 2014-2017
Figure 9.29. Advaxis, Inc.: Product Segments Share (%), 2017
Figure 10.1 World Cancer Immunotherapy by Technology: ($m), 2018-2029
Figure 10.2 World Cancer Immunotherapy by Application: ($m), 2018-2029
Figure 10.3 World Cancer Immunotherapy by End-User: ($m), 2018-2029
Figure 10.4 World Cancer Immunotherapy by Geography: ($m), 2018-2029



★調査レポート[ウエハーレベルパッケージングの世界市場2019-2029：モノクローナル抗体、サイトカイン・免疫調節剤、免疫チェックポイント阻害剤、細胞療法、腫瘍崩壊性ウイルス免疫療法、肺がん、乳がん、大腸がん、黒色腫、前立腺がん、頭頸部がん、病院、がん研究センター、診療所] ( Global Cancer Immunotherapy Market Forecast 2019-2029 : Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centres, Clinics / VGN902094) 販売に関する免責事項
[ウエハーレベルパッケージングの世界市場2019-2029：モノクローナル抗体、サイトカイン・免疫調節剤、免疫チェックポイント阻害剤、細胞療法、腫瘍崩壊性ウイルス免疫療法、肺がん、乳がん、大腸がん、黒色腫、前立腺がん、頭頸部がん、病院、がん研究センター、診療所] ( Global Cancer Immunotherapy Market Forecast 2019-2029 : Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centres, Clinics / VGN902094) についてEメールでお問い合わせ
◆関連調査資料◆
  • ウエハーレベルパッケージングの世界市場2019-2029：包装技術別（3DTSVWLP、2.5DTSVWLP、WLCSP、ナノWLP、その他）、統合種類別（ファンインWLP、ファンアウトWLP）、業種別（エレクトロニクス、IT、通信、産業、自動車、その他）予測航空宇宙、防衛、ヘルスケア、その他）、主要企業プロファイル、地域別、国内主要市場分析
    VGN902086 / visiongain / 2019年1月 / ...• Do you need definitive Wafer Level Packaging market data?• Succinct Wafer Level Packaging market analysis? • Technological insight? • Clear competitor analysis? • Actionable business recommendations? Read on to discover how this definitive report can transform your own research and save you time. The recent news on wafer level packaging industry: China-based OSAT (outsourced semiconductor assembly and test) companies looking to tap high-end packaging segments”, has led Visiongain to publish this timely report. The $4.7Bn market is expected to grow significantly by 2029 because of wide range of end-user applications. Key strategies adopted by the key players in this...
  • 泌尿器科用機器の世界市場予測（～2026）：尿失禁、良性前立腺過形成（BPH）、腎臓結石、前立腺がん
    VGAIN61209 / visiongain / 2016年12月 / 当調査レポートでは、泌尿器科用機器の世界市場について調査・分析し、泌尿器科用機器の世界市場規模、市場動向、市場予測、市場環境分析、専門家の見解、関連企業情報などを含め、以下の構成でお届けいたします。...The global urology devices market is expected to grow at a CAGR of 5.8% from 2020-2026 and CAGR of 6.2% from 2016-2020. The market is expected to grow at a CAGR of 6.0% from 2016 to 2026. The market is estimated at $6,126.4 million in 2016, $7,793.0 million in 2020, and $10,971.3 million in 2026. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new report you find 200-page report you will receive 91 tables and 80 charts – all unavailable elsewhere. The 200...
  • バッテリー式電動輸送機器（BEV)の世界市場2019-2029：車種別（バッテリー式電動乗用車、バッテリー式電動小型商用車、バッテリー式電動重量運搬車、バッテリー式電動二輪車）、地域別予測
    VGN902013 / visiongain / 2018年11月 / ...• Do you need definitive battery electric vehicle market data?• Succinct battery electric market analysis? • Sectoral insights? • Clear competitor analysis? • Actionable business recommendations? Read on to discover how this definitive report can transform your research and save you time. The increasing need to reduce vehicular emissions, decreasing battery prices, and the introduction of stringent regulations by government bodies, has led visiongain to publish this timely report. Market players in the global industry are introducing fuel-efficient and low-cost battery electric vehicles to cater to the growing consumer needs. These market players are also integrating advanced technologies such as...
  • 乳がん治療薬の世界市場：モノクローナル抗体、ホルモン、化学療法、キナーゼ阻害剤、その他
    VGAIN6041534 / visiongain / 2016年3月 / ...Breast Cancer Therapies – Discover From 2016 What Revenues Are PossibleAre you interested in the breast cancer drug market’s future? If so, you find that sales forecasting from 2016 in our new report. See there what is possible for those products and companies. You also explore trends, results and R&D, discovering opportunities and prospects. Visiongain’s study gives revenue predictions to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and revenues those anti cancer drugs can achieve. See what is possible in that leading drugs market....
  • 生物製剤の世界市場2018-2028：タンパク質治療薬、モノクローナル抗体、融合タンパク質、再生医療、インスリン、その他の組み換えホルモン、血漿・組み換え凝固因子、インターフェロン、酵素補充、幹細胞療法、組織工学製品、遺伝子治療
    VGN902103 / visiongain / 2018年11月 / ...The global biologics market is estimated to reach $250bn in 2023. The market is expected to grow at a CAGR of 4.8% from 2018 to 2023. In 2017, the monoclonal antibodies submarket held 36.3% share of the global biologics market. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 303-page report you will receive 166 charts– all unavailable elsewhere. The 303-page report provides clear detailed insight into the global biologics market. Discover the key drivers and challenges affecting the market. By ordering and...
  • 養鶏飼料の世界市場2019-2029：ブロイラー、七面鳥、産卵鶏、アミノ酸、ビタミン、飼料酵素、抗生物質、抗酸化剤、飼料酸性化剤
    VGN902081 / visiongain / 2019年1月 / ...The global poultry feed market is estimated to reach $322bn in 2024. The broiler poultry feed submarket is expected to hold 64% share of the global poultry feed market in 2024. The global poultry feed market is estimated to grow at a CAGR of 5.5% through the forecast period. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 140-page report you will receive 120 charts– all unavailable elsewhere. The 140-page report provides clear detailed insight into the global poultry feed market. Discover the...
  • タイヤ由来燃料(TDF)の世界市場2019-2029：タイヤ別（細断タイヤ、全タイヤ）、エンドユーザー別（セメント製造、紙・パルプ、ユーボイラー）、及び国別分析・予測、主要関連国・企業の予測
    VGN902068 / visiongain / 2019年1月 / ...Tire derived fuel (TDF) is composed of scrap or misshapen tires which can be either shredded or chipped to between 1 and 4 inches. These scrap tires can be collected from manufacturers, retail partners, local councils and processed at various plants. After they have been shredded, the TDF can be mixed with coal and other fuels such as wood and chemical waste. These mixtures can then be burned in concrete kilns, paper mills or even power plants. According to the Environmental Protection Agency, TDF produces the same amount of energy as oil and up to 25% more energy than coal,...
  • 主要医薬品企業シリーズ：喘息・COPD治療薬の上位20社2019-2029：企業概要、市販品、製品パイプライン、収益、予測
    VGN902096 / visiongain / 2018年12月 / ...The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $47bn by 2029. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 160-page report you will receive 86 charts– all unavailable elsewhere. The 160-page report provides clear detailed insight into the Top 20 asthma & COPD companies. Discover the key drivers and challenges affecting the market. By ordering and reading our brand-new report today you stay better informed and ready to act. Report Scope...
  • 軍事展開型インフラストラクチャーの世界市場2019-2029：インフラストラクチャ種類別（ISRインフラストラクチャ・シェルター）、シェルター種類別（コンテナ型スチール製シェルター、軽量展開型構造物、防弾複合シェルター、車両搭載シェルター）、地域別予測、主要企業プロファイル
    VGN902041 / visiongain / 2019年1月 / ...The latest report from business intelligence provider Visiongain offers comprehensive analysis of the global Military Deployable Infrastructure market. Visiongain assesses that this market will generate revenues of US$27,938 Mn in 2019. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain’s new study tells you and tells you NOW. In this brand new report, you find 73 in-depth tables and 90 figures. The 187-page report provides clear detailed insight into the global military deployable infrastructure market. Discover the key drivers and challenges affecting the market. By ordering...
  • ガス絶縁変圧器の世界市場2019-2029：設置種類別（屋内、屋外）、エンドユーザー別（ユーティリティ、ユーティリティ以外）および変圧器種類別（三相、単相/二相、多相）、及び主要企業プロファイルと地域、主要国内市場分析
    VGN902074 / visiongain / 2018年11月 / ...• Do you need definitive gas-insulated transformers market data?• Succinct gas-insulated transformers market analysis? • Technological insight? • Clear competitor analysis? • Actionable business recommendations? Read on to discover how this definitive report can transform your own research and save you time. The increased focus on a more efficient energy grid infrastructure has led Visiongain to publish this timely report. The market of power transformers is expected to flourish in the next few years because of the need for efficient energy usage and also a greater renewable energy penetration into the energy mix is expected to feed through in the...

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆